New approaches for identifying antiarrhythmic drug targets

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 1, 2004, Pages 1-5

  Gilmour Jr , Robert F ^a  

^a Cornell University ^*  (United States)

Author keywords

Action potential duration; Antiarrhythmic drugs; Calcium channel antagonists; Potassium channel antagonists; Restitution; Ventricular fibrillation

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRETYLIUM; CALCIUM CHANNEL BLOCKING AGENT; INOSITOL PHOSPHATE; VERAPAMIL;

ACTION POTENTIAL; ANTIARRHYTHMIC ACTIVITY; CAUSE OF DEATH; DEVELOPED COUNTRY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG TARGETING; EDITORIAL; ELECTROCARDIOGRAM; EXPERIMENTAL MODEL; HEART EXCITATION; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HUMAN; NERVE BLOCK; QT INTERVAL; REENTRY ARRHYTHMIA; SIDE EFFECT; SUDDEN DEATH;

ACTION POTENTIALS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CLINICAL TRIALS; DEATH, SUDDEN, CARDIAC; DOGS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; GENETIC VECTORS; HEART CONDUCTION SYSTEM; ION CHANNEL GATING; MODELS, CARDIOVASCULAR; PHOSPHORYLATION; POTASSIUM; POTASSIUM CHANNELS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSDUCTION, GENETIC; VENTRICULAR FIBRILLATION;

EID: 1242329940     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/eott.8.1.1.26406     Document Type: Editorial

References (61)

1. ZIPES DP, WELLENS HJ: Sudden cardiac death. Circulation (1998) 98:2334-2351.
2. MYERBURG RJ: Life-threatening ventricular arrhythmias: the link between epidemiology and pathophysiology. In: Cardiac Electrophysiology: From Cell to Bedside. Zipes DP, Jalife J (Eds), WB Saunders Company, Philadelphia (1995):723-729.
3. WINFREE AT: Evolving perspectives during 12 years of electrical turbulence. Chaos (1998) 8:1-20.
4. ALLESSIE MA, BONKE FI, SCHOPMAN FJ: Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The 'leading circle' concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ. Res. (1977) 41:9-18.
5. CHEN PA, WOLF PD, DIXON EG et al.: Mechanism of ventricular vulnerability to single premature stimuli in open-chest dogs. Circ. Res. (1988) 62:1191-1209.
6. FRAZIER DW, WOLF PD, WHARTON JM, TANG ASL, SMITH WM, IDEKER RE: Stimulus-induced critical point. Mechanism for electrical initiation of re-entry in normal canine myocardium. J. Clin. Invest. (1989) 83:1039-1052.
7. KRINSKY VI, EFIMOV IR: Vortices with linear cores in mathematical models of excitable media. Physica D (1992) A188:55-60.
8. WITKOWSKI FX, LEON LJ, PENKOSKE PA et al.: Spatiotemporal evolution of ventricular fibrillation. Nature (1998) 392:78-82.
9. JANSE J, WIT AL: Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol. Rev. (1989) 69:1049-1169.
10. ANTZELETVITCH C: Electrical heterogeneity, cardiac arrhythmias, and the sodium channel. Circ. Res. (2000) 87:964-965.
11. NOLASCO JB, DAHLEN RW: A graphic method for the study of alternation in cardiac action potentials. J. Appl. Physiol. (1968) 25:191-196.
12. GUEVARA MR, WARD G, SHRIER A, GLASS L: Electrical alternans and period doubling bifurcations. IEEE Comp. Cardiol. (1984) 562:167-170.
13. CHIALVO DR, GILMOUR RF Jr, JALIFE J: Low dimensional chaos in cardiac tissue. Nature (1990) 343:653-657.
14. NEARING BD, HUANG AH, VERRIER RL: Dynamic tracking of cardiac vulnerability by complex demodulation of the T wave. Science (1991) 252:437-440.
15. KARMA A: Spiral breakup in model equations of action potential propagation in cardiac tissue. Phys. Rev. Lett. (1993) 71:1103-1106.
16. KARMA A: Electrical alternans and spiral wave breakup in cardiac tissue. Chaos (1994) 4:461-472.
17. ROSENBAUM DS, JACKSON LE, SMITH JM, GARAN H, RUSKIN JN, COHEN RJ: Electrical alternans and vulnerability to ventricular arrhythmias. N. Engl. J. Med. (1994) 330:235-241.
18. KOLLER ML, RICCIO ML, GILMOUR RF Jr: Dynamic restitution of action potential duration during electrical alternans and ventricular fibrillation. Am. J. Physiol. (1998) 275:H1635-H1642.
19. PASTORE JM, GIROUARD SD, LAURITA KR, AKAR FG, ROSENBAUM DS: Mechanism linking T-wave alternans to the genesis of cardiac fibrillation. Circ. Res. (1999) 99:1385-1394.
20. GILMOUR RF Jr, CHIALVO DR: Electrical restitution, critical mass, and the riddle of fibrillation. J. Cardiovasc. Electrophysiol. (1999) 10:1087-1089.
21. PANFILOV A, PERTSOV A: Ventricular fibrillation: evolution of the multiple wave hypothesis. Philos. Trans. R. Soc. Lond. A (2001) 359:1315-1325.
22. FENTON FH, CHERRY EM, HASTINGS HM, EVANS SJ: Multiple mechanisms of spiral wave breakup in a model of cardiac electrical activity. Chaos (2002) 12(3):852-892.
23. WEISS JN, CHEN PS, QU Z, KARAGUEUZIAN HS, LIN SF, GARFINKEL A: Electrical restitution and cardiac fibrillation. J. Cardiovasc. Electrophysiol. (2002) 13:292-295.
24. WATANABE MA, FENTON FH, EVANS SJ, HASTINGS HM, KARMA A: Mechanisms for discordant alternans. J. Cardiovasc. Electrophysiol. (2001) 12:196-206.
25. QU Z, GARFINKEL A, CHEN PS, WEISS JN: Mechanisms of discordant alternans and induction of re-entry in simulated cardiac tissue. Circulation (2000) 102:1664-1670.
26. FOX JJ, RICCIO ML, HUA F, BODENSCHATZ E, GILMOUR RF Jr: Spatiotemporal transition to conduction block in canine ventricle. Circ. Res. (2002) 90:289-296.
27. FOX JJ, RICCIO DL, DRURY P, WERTHMAN A, GILMOUR RF Jr: Dynamic mechanism for conduction block in heart tissue. NJ Phys. (2003) 5:101.1-101.14.
28. KARAGUEUZIAN HS, KHAN SS, HONG K et al.: Action potential alternans and irregular dynamics in quinidine-intoxicated ventricular muscle cells. Implications for ventricular proarrhythmia. Circulation (1993) 87:1661-1672.
29. PANFILOV A: Spiral breakup as a model of ventricular fibrillation. Chaos (1998) 8:57-64.
30. QU Z, WEISS JN, GARFINKEL A: Cardiac electrical restitution properties and stability of re-entrant spiral waves: a simulation study. Am. J. Physiol. (1999) 276:H269-H283.
31. RICCIO ML, KOLLER ML, GILMOUR RF Jr: Electrical restitution and spatiotemporal organization during ventricular fibrillation. Circ. Res. (1999) 84:955-963.
32. GARFINKEL A, KIM YH, VOROSHILOVSKY O et al.: Preventing ventricular fibrillation by flattening cardiac restitution. Proc. Natl. Acad. Sci. USA (2000) 97:6061-6066.
33. o on electrical restitution and activation dynamics during ventricular fibrillation. Am. J. Physiol. Heart Circ. Physiol. (2000) 279:H2665-H2672.
34. 2+ dynamics and the stability of ventricular tachycardia. Biophys. J. (1999) 77:2930-2941.
35. GOLDHABER JI, MOTTER C, DUONG TK, WEISS JN: Cellular basis of action potential duration alternans: role of the L-type calcium current and intracellular calcium cycling. Circulation (2002) 106:228-228.
36. FOX JJ, MCHARG JL, GILMOUR RF Jr: Ionic mechanism of cardiac alternans. Am. J. Physiol. (2002) 282:H516-H530.
37. + channels. Mol. Pharmacol. (1998) 53:220-230.
38. + channel activity is regulated by changes in phosphatidyl inositol 4,5-bisphosphate. Circ. Res. (2001) 89:1168-1176.
39. KIEHN J: Regulation of the cardiac repolarizing HERG potassium channel by protein kinase A. Trends Cardiovasc. Med. (2001) 10:205-209.
40. Kr, through a reduction in C-type inactivation in guinea pig ventricular myocytes. J. Physiol. (Lond.) (2000) 522:391-402.
41. MARX SO, KUROKAWA J, REIKEN S et al.: Requirement of a macromolecular signaling complex for β adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science (2002) 295:496-499.
42. + current. Differential sensitivity to block by Class III antiarrhythmic agents. J. Gen. Physiol. (1990) 96:195-215.
43. ROCCHETTI M, BESANA A, GURROLA GB, POSSANI LD, ZAZA A: Rate dependency of delayed rectifier currents during the guinea-pig ventricular action potential. J. Physiol. (2001) 534:721-732.
44. GINTANT GA: Characterization and functional consequences of delayed rectifier current transient in ventricular repolarization. Am. J. Physiol. (2000) 278:H806-H817.
45. Ks in electrical heterogeneity. Am. J. Physiol. (1995) 268:H604-H613.
46. CLAY JR, OGBAGHEBRIEL A, PAQUETTE T, SASYNIUK BI, SHRIER A: A quantitative description of the E-4031-sensitive repolarization current in rabbit ventricular myocytes. Biophys. J. (1995) 69:1830-1837.
47. NUSS HB, MARBAN E, JOHNS DC: Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes. J. Clin. Invest. (1999) 103:889-896.
48. HUA F, JOHNS DC, GILMOUR RF Jr: Suppression of electrical alternans by overexpression of HERG in canine ventricular myocytes. Am. J. Physiol. In Press.
49. WALDO AL, CAMM AJ, DERUYTER H et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With ORal D-sotalol. Lancet (1996) 348:7-12.
50. HONDEGHEM LM, SNYDERS DJ: Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation (1990) 81:686-690.
51. + channel by the gastrointestinal prokinetic agent cisapride. Am. J. Physiol. (1997) 273:H2534-H2538.
52. ROY M, DUMAINE R, BROWN AM: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation (1996) 94:817-823.
53. MITCHESON JS, CHEN J, LIN M, CULBERSON C, SANGUINETTI MC: A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA (2000) 97:12329-12333.
54. RODEN DM: Acquired long QT syndromes and the risk of proarrhythmia. J. Cardiovasc. Electrophysiol. (2000) 11:938-940.
55. KEATING MT, SANGUINETTI MC: Molecular genetic insights into cardiovascular disease. Science (1996) 272:681-685.
56. CURRAN ME, SPLAWSKI I, TIMOTHY KW, VINCENT GM, GREEN ED, KEATING MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell (1995) 80:795-803.
57. RODEN DM, BALSER JR: A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology. Cardiovasc. Res. (1999) 44:242-246.
58. Kr potassium channel. Cell (1995) 81:299-307.
59. ECHT DS, LIEBSON PR, MITCHELL LB et al.: Mortality and morbidity in patients receiving encainide, flecainide or placebo: the cardiac arrhythmia suppression trial. N. Engl. J. Med. (1991) 324:781-788.
60. YUSUF S, WITTES J, FRIEDMAN L: Overview of results of randomized clinical trials in heart disease: I. Treatments following myocardial infarction. JAMA (1988) 260:2088-2095.
61. HELD PH, YUSUF S: In: Cadiovascular Pharmacology and Therapeutics. Singh BN et al. (Eds), Churchill Livingstone, New York (1994):525-533.